OTC Markets OTCPK - Delayed Quote USD

Biotest Aktiengesellschaft (BIESF)

32.00
0.00
(0.00%)
At close: May 19 at 4:00:00 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
635,200
726,200
684,600
516,100
515,600
Cost of Revenue
487,900
502,400
404,300
391,200
434,900
Gross Profit
147,300
223,800
280,300
124,900
80,700
Operating Expense
136,400
138,100
151,000
133,400
132,800
Operating Income
10,900
85,700
129,300
-8,500
-52,100
Net Non Operating Interest Income Expense
-29,200
-32,800
-39,100
-22,800
-15,700
Pretax Income
-25,700
46,500
106,300
-30,800
-62,600
Tax Provision
-1,100
20,200
-20,700
800
700
Net Income Common Stockholders
-24,500
26,400
127,000
-32,100
-63,800
Diluted NI Available to Com Stockholders
-24,500
26,400
127,000
-32,100
-63,800
Basic EPS
-0.63
--
3.20
-0.81
-1.61
Diluted EPS
-0.63
--
3.20
-0.81
-1.61
Basic Average Shares
39,332.51
--
39,571.45
39,571.45
39,571.45
Diluted Average Shares
39,571.45
--
39,571.45
39,571.45
39,571.45
Total Operating Income as Reported
18,700
94,500
143,500
-16,600
-47,100
Total Expenses
624,300
640,500
555,300
524,600
567,700
Net Income from Continuing & Discontinued Operation
-24,500
26,400
127,000
-31,700
-63,400
Normalized Income
-20,192.61
29,290
115,100
-33,315
-65,080
Interest Income
5,200
2,000
2,000
800
200
Interest Expense
32,900
33,300
40,000
19,700
13,200
Net Interest Income
-29,200
-32,800
-39,100
-22,800
-15,700
EBIT
7,200
79,800
146,300
-11,100
-49,400
EBITDA
7,200
120,400
182,200
24,700
-18,300
Reconciled Cost of Revenue
487,900
502,400
404,300
391,200
434,900
Reconciled Depreciation
--
40,600
35,900
35,800
31,100
Net Income from Continuing Operation Net Minority Interest
-24,500
26,400
127,000
-31,700
-63,400
Total Unusual Items Excluding Goodwill
-4,500
-3,400
14,000
1,900
2,400
Total Unusual Items
-4,500
-3,400
14,000
1,900
2,400
Normalized EBITDA
11,700
123,800
168,200
22,800
-20,700
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-192.61
-510
2,100
285
720
12/31/2021 - 1/9/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SHJBF Shanghai Junshi Biosciences Co., Ltd.
1.9700
0.00%
 
IVBIY Innovent Biologics Inc.
26.11
0.00%
 
NURPF Neuren Pharmaceuticals Limited
8.14
0.00%
 
CLVLY Clinuvel Pharmaceuticals Limited
7.00
-3.05%
 
KROS Keros Therapeutics, Inc.
14.14
+0.28%
 
CGON CG Oncology, Inc.
26.56
+6.84%
 
MIRM Mirum Pharmaceuticals, Inc.
45.34
+1.00%
 
RARE Ultragenyx Pharmaceutical Inc.
37.35
+3.21%
 
ACLX Arcellx, Inc.
60.54
+3.47%
 
AGIO Agios Pharmaceuticals, Inc.
30.17
+1.11%